SCHEMBL382167

SCHEMBL382167

CCOC(=O)c1cc(C)oc1-c1cccc(O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
JAK2 O60674 1/20 0.48
JAK3 P52333 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 2/20 0.48
ALDH1A1 P00352 4/20 0.47
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
MIF P14174 1/20 0.46
PFKFB3 Q16875 1/20 0.46
CSNK1D P48730 1/20 0.46
TSHR P16473 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11718771 0.86 ALDH1A1 (0.60) MEN1KMT2AGAAALDH1A1TSHR
SCHEMBL381031 0.84 ALDH1A1 (0.54) CA12CA2CA7CA9CA14
SCHEMBL381258 0.80 FAAH (0.47) MEN1KMT2AALDH1A1CYP3A4CYP2C19
SCHEMBL381279 0.75 FAAH (0.63) KMT2AALDH1A1
SCHEMBL23091155 0.74 ERN1 (0.55) MEN1KMT2AGAAALDH1A1TSHR
SCHEMBL30501683 0.74 ERN1 (0.55) MEN1KMT2AGAAALDH1A1TSHR
SCHEMBL3900684 0.74 NPC1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL29858672 0.73 ALDH1A1 (0.59) MEN1KMT2AGAAALDH1A1TSHR
SCHEMBL5846397 0.73 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL6177272 0.72 CYP1A1 (0.56) MEN1KMT2AALDH1A1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252865-A1 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2012-10-04 US disclosed
EP-2408743-A1 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2012-01-25 EP disclosed
WO-2010105930-A1 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252865-A1 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS ACHE, CHRNA10, CHRNA5 ALOX5 1412/4885CA12 647/4885CA1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.